Which RhIL-11 Injection(Oprelvekin) Supplier Is Good?
RhIL-11 Injection(Oprelvekin), CAS No.: 145941-26-0, (Recombinant Human Interleukin-11) – A Drug To Increase Platelet Count, RhIL-11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial
Product Description:
RhIL-11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial is a white to off-white lyophilized powder that is available in three different quantities. The powder is sterile and is intended for intravenous injection. The product is packed in glass vials and is sealed with a rubber stopper.
1. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Website:https://www.jiuyuangene.net/
As a frontrunner in biopharmaceutical development, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has established itself as a key player in China's pharmaceutical landscape. With a strong focus on research and innovation, the company specializes in therapeutic proteins, particularly in the fields of hematology and oncology. Its flagship product, a recombinant human granulocyte colony-stimulating factor, is a testament to its advanced bioengineering capabilities. Operating state-of-the-art production facilities that comply with international GMP standards, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. ensures the highest level of product quality and consistency. The company's commitment to advancing biotech medicines makes it a crucial partner in the global healthcare ecosystem, providing essential treatments to patients worldwide.
2. CR Angde Biopharmaceutical Co., Ltd.
Angde is a medium-sized biotech firm focusing on recombinant protein drugs. Its flagship product Baijieyi (rhIL-11 for injection) launched in 2008, treats chemotherapy-induced thrombocytopenia. As a national Class I new drug with independent intellectual property, it features high purity and stable efficacy. The company operates GMP facilities, employs 140+ staff, and holds Shandong Provincial Tech Center certification. Scale and specialization fit medium-sized positioning, with mature production and consistent quality for global supply.
3.Beijing SL Pharmaceutical Co., Ltd.
SL Pharma is a medium-sized listed biotech with 20+ years in rhIL-11. Its product Maigeer (rhIL-11 injection) (0.75mg/1.5mg) treats solid tumor and leukemia-related thrombocytopenia. Approved in 2003, it has wide clinical recognition. The company maintains compact R&D and GMP production, with steady sales and moderate market share, fitting medium-sized supplier criteria.
4.Xiamen Amoytop Biotech Co., Ltd.
Amoytop is a medium-sized biotech specializing in hematopoietic factors. Its rhIL-11 product Terkang is indicated for grade III/IV thrombocytopenia post-chemotherapy. With GMP-certified plants and national reference standard supply capacity, it provides API and finished dosage forms. Focused on recombinant proteins, moderate scale and stable quality make it a key medium-sized supplier.
5.Zhejiang Hisun Pharmaceutical Co., Ltd.
Hisun is a medium-sized comprehensive pharma with biotech division. Its rhIL-11 injection covers standard specifications, produced via strict GMP. Focused on oncology supportive care, it has complete quality systems and global registration support. Not a industry giant, it maintains moderate production scale and stable export volume for reliable global supply.
6.Shanghai Salubris Biotech Co., Ltd.
Salubris is a medium-sized biotech focusing on blood products and recombinant proteins. Its rhIL-11 injection targets chemotherapy-induced thrombocytopenia, with optimized purification for high purity and low endotoxin. The company has professional R&D and quality teams, compliant production lines, and steady clinical market expansion, fitting medium-sized supplier requirements.
7.Tonghua Dongbao Pharmaceutical Co., Ltd.
Dongbao is a medium-sized biopharma with diversified recombinant protein lines. Its rhIL-11 injection is produced in GMP facilities, with stable quality and complete pharmacopoeia compliance. Focused on hematology and diabetes drugs, it has balanced operations and moderate market presence, serving as a dependable medium-sized supplier without industry giant status.